Compare Eli Lilly And Co (LLY) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Ross Stores, Inc. — how do they compare? Eli Lilly And Co trades at $1,224.23 (market cap $1.08T), while Ross Stores, Inc. trades at $249.61 (market cap $80.78B). The key difference: Eli Lilly And Co is far larger — about 13.4× Ross Stores, Inc.'s market cap, and Ross Stores, Inc. pays the higher dividend (0.71%). Which is the better fit depends on your goals.
| LLY | ROST | |
|---|---|---|
Market Cap | $1.08T | $80.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.24K | $255.23 |
52-Week Low | $639.43 | $144.67 |
Enterprise Value | $1.13T | $81.37B |
Dividend Yield | 0.57% | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Ross Stores (ROST) trades at $254.83, near its consensus price target of $259.00, with a slight 0.16% decline. The stock shows strong fundamentals, including a 9.74% net income margin and 38.98% ROE for 2025, with recent quarterly earnings consistently beating estimates. Technical indicators are bullish, supported by positive moving averages and recent store expansion news.
The outlook remains positive due to robust earnings growth and analyst buy ratings (63.83% consensus). Key risks include high valuation multiples (P/E of 35.17) and competitive pressures in discount retail. Upside potential exists if Q2 2026 earnings beat expectations, but macroeconomic headwinds could pressure consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
